Safety and immunogenicity of Thailand Government Pharmaceutical Organization (GPO) produced, COVID-19 vaccine, 10 μg HXP-GPOVac: A Phase III, double-blind, randomized trial in comparison with VAXZEVRIA. (PubMed, Vaccine) - Oct 14, 2026 - "HXP-GPOVac was well-tolerated and demonstrated non-inferior immunogenicity compared with VAXZEVRIA at 14 days after vaccination. These findings provide rationale for larger studies to assess HXP-GPOVac clinical efficacy."
Journal • P3 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
|
|
Bruce L Innis; Chakrarat Pittayawonganon; Christina S Polyak; Colleen Scott; Darunee Ditsungneon; Isariya Techatanawat; Jiraphut Kittiwatanachod; Jorge Flores; Kanlaya Sornwong; Kriengkrai Prasert; Laina D Mercer; Martha P Montgomery; Piengthong Narakorn; Ponthip Wirachwong; Prabda Praphasiri; Rama Raghunandan; Somchaiya Surichan; Sopon Iamsirithaworn; Supakit Sirilak; Suriya Naosri; Sutthichai Nakphook; William W Davis
|